Selected data models

You must log in to select data models for download or further analysis.

9 Search results.
Relevance Rating New first Old first

Diary Card General Symptoms All groups Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381 - Diary Card General Symptoms All groups

- 7/29/17 - 1 form, 3 itemgroups, 41 items, 1 language
Itemgroups: Adverse Events General Symptoms, Symptoms, Medication
Study part: Diary Card General Symptoms All groups. A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381

Diary Card Local Symptoms Group Hib-MenCY or Hib-MenC Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381 - Diary Card Local Symptoms Group Hib-MenCY or Hib-MenC

- 7/29/17 - 1 form, 2 itemgroups, 42 items, 1 language
Itemgroups: Adverse Events Symptoms Local, symptoms local
Study part: Diary Card Local Symptoms Group Hib-MenCY or Hib-MenC. A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381

Diary Card Local Symptoms Group Control Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381 - Diary Card Local Symptoms Group Control

- 7/29/17 - 1 form, 2 itemgroups, 42 items, 1 language
Itemgroups: Adverse Events Symptoms Local, symptoms local
Study part: Diary Card Local Symptoms Group Control. A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381

Solicited Adverse Events- General Symptoms All Groups Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381 - Solicited Adverse Events- General Symptoms All Groups

- 7/17/17 - 1 form, 1 itemgroup, 35 items, 1 language
Itemgroup: Adverse Events General Symptoms
Study part: Solicited Adverse Events- General Symptoms All Groups. A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381

Solicited Adverse Events- Local Symptoms Group Hib-MenCY or Hib-MenC Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381 - Solicited Adverse Events- Local Symptoms Group Hib-MenCY or Hib-MenC

- 7/17/17 - 1 form, 1 itemgroup, 44 items, 1 language
Itemgroup: Adverse Events Symptoms Local
Study part: Solicited Adverse Events- Local Symptoms Group Hib-MenCY or Hib-MenC. A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381

Solicited Adverse Events- Local Symptoms Group Control Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381 - Solicited Adverse Events- Local Symptoms Group Control

- 7/17/17 - 1 form, 1 itemgroup, 44 items, 1 language
Itemgroup: Adverse Events Symptoms Local Group Control
Study part: Solicited Adverse Events- Local Symptoms Group Control. A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381

Serious Adverse Events Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381 - Serious Adverse Events

- 7/17/17 - 1 form, 13 itemgroups, 66 items, 1 language
Itemgroups: Serious Adverse Events, Document section, Seriousness, Demography Data, Document section, causes of SAE, Medical Conditions, risk factors, Concomitant Medications, Document section, Document section, Document section, follow-up information SAE
Study part: Serious Adverse Events. A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381

Non- Serious Adverse Events Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381 - Non- Serious Adverse Events

- 7/17/17 - 1 form, 1 itemgroup, 13 items, 1 language
Itemgroup: Non- Serious Adverse Events
Study part: Non- Serious Adverse Events. A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381

Adverse Events- Post- Vaccination Observation Booster Dose Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381 - Adverse Events- Post- Vaccination Observation Booster Dose

- 7/16/17 - 1 form, 1 itemgroup, 2 items, 1 language
Itemgroup: Adverse Events
Study part: Adverse Events- Post- Vaccination Observation Booster Dose. A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial